ENOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril

European Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2013, Pages 167-177

  Silva, P S ^a   Fontana, V ^b   Luizon, M R ^b   Lacchini, R ^b   Silva Jr , W A ^b   Biagi, C ^c   Tanus Santos, J E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Santa Casa of Aracatuba   (Brazil)

Author keywords

BDKRB2; Enalapril; eNOS; Hypertension; Polymorphisms

Indexed keywords

ADENINE; BRADYKININ B2 RECEPTOR; CYTOSINE; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANINE; THYMINE;

ADULT; ARTICLE; BRADYKININ RECEPTOR B2 GENE; DNA POLYMORPHISM; DNA SEQUENCE; DRUG EFFECT; ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ENALAPRIL; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; RECEPTOR, BRADYKININ B2;

EID: 84873732707     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1326-2     Document Type: Article

References (57)

1. Lawes CM, Vander Hoorn S, Rodgers A (2008) Global burden of blood-pressure-related disease, 2001. Lancet 371(9623):1513-1518 (Pubitemid 351626187)
2. Linz W, Wohlfart P, Scholkens BA, Malinski T, Wiemer G (1999) Interactions among ACE, kinins and NO. Cardiovasc Res 43(3):549-561 (Pubitemid 29369254)
3. Mason RP, Cockcroft JR (2006) Targeting nitric oxide with drug therapy. J Clin Hypertens (Greenwich) 8(12 Suppl 4):40-52
4. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A (2005) The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99(1):6-38 (Pubitemid 41366887)
5. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R (2001) Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol 33(3):395-403 (Pubitemid 32538997)
6. Comini L, Bachetti T, Cargnoni A, Bastianon D, Gitti GL, Ceconi C, Ferrari R (2007) Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacol Res 56(1):42-48 (Pubitemid 46990929)
7. De Gennaro CV, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G (2005) Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol 516(3):253-259 (Pubitemid 40922746)
8. Miguel-Carrasco JL, Monserrat MT, Mate A, Vazquez CM (2010) Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur J Pharmacol 632(1-3):65-72
9. Hornig B, Kohler C, Drexler H (1997) Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95(5):1115-1118 (Pubitemid 27097818)
10. Joshi MS, Mineo C, Shaul PW, Bauer JA (2007) Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 21(11):2655-2663 (Pubitemid 47372733)
11. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, Harada M, Kajiyama N, Kishimoto I, Kuwahara K, Hino J, Ogawa E, Hamanaka I, Kamitani S, Takahashi N, Kawakami R, Kangawa K, Yasue H, Nakao K (2000) Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-> C mutation associated with coronary spastic angina. Hum Mol Genet 9(18):2629-2637
12. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K (1999) T-786-> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99(22):2864-2870 (Pubitemid 29258973)
13. Zhang MX, Zhang C, Shen YH, Wang J, Li XN, Chen L, Zhang Y, Coselli JS, Wang XL (2008) Effect of 27nt small RNA on endothelial nitric-oxide synthase expression. Mol Biol Cell 19(9):3997-4005
14. Zhang MX, Zhang C, Shen YH, Wang J, Li XN, Zhang Y, Coselli J, Wang XL (2008) Biogenesis of short intronic repeat 27-nucleotide small RNA from endothelial nitric-oxide synthase gene. J Biol Chem 283(21):14685-14693
15. Metzger IF, Ishizawa MH, Rios-Santos F, Carvalho WA, Tanus-Santos JE (2011) Endothelial nitric oxide synthase gene haplotypes affect nitrite levels in black subjects. Pharmacogenomics J 11(6):393-399
16. Metzger IF, Sertorio JT, Tanus-Santos JE (2007) Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43(6):987-992 (Pubitemid 47223635)
17. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE (2005) Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 15(8):565-570 (Pubitemid 41044242)
18. Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C, Lonn E, Charbonneau F, Anderson TJ (2002) The T-786-> C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 39(4):919-922 (Pubitemid 34437550)
19. Nejatizadeh A, Kumar R, Stobdan T, Goyal AK, Sikdar S, Gupta M, Javed S, Pasha MA (2008) Endothelial nitric oxide synthase gene haplotypes and circulating nitric oxide levels significantly associate with risk of essential hypertension. Free Radic Biol Med 44(11):1912-1918
20. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G, Tanus-Santos JE (2008) eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9(10):1467-1473
21. Vasconcellos V, Lacchini R, Jacob-Ferreira AL, Sales ML, Ferreira-Sae MC, Schreiber R, Nadruz W, Tanus-Santos JE (2010) Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy. DNA Cell Biol 29(4):171-176
22. Lee YC, Wu WJ, Liu CC, Wang CJ, Li WM, Huang CH, Yeh HC, Ke HL, Huang SP (2009) The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J Sex Med 6(11):3158-3165
23. Napoli C, Ignarro LJ (2007) Polymorphisms in endothelial nitric oxide synthase and carotid artery atherosclerosis. J Clin Pathol 60(4):341-344 (Pubitemid 46596549)
24. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos JE (2006) Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186(2):428-432
25. Sandrim VC, de Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE (2006) Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 189(1):241-246 (Pubitemid 44441291)
26. Braun A, Kammerer S, Maier E, Bohme E, Roscher AA (1996) Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 33(1-3):32-35 (Pubitemid 26247894)
27. Braun A, Maier E, Kammerer S, Muller B, Roscher AA (1996) A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene. Hum Genet 97(5):688-689 (Pubitemid 26112042)
28. Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, Hawe E, Palmen JM, Wootton PT, Miller GJ, Humphries SE, Montgomery HE (2003) Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J 24(18):1672-1680 (Pubitemid 37174908)
29. Hallberg P, Lind L, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H (2003) B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 21(3):621-624 (Pubitemid 36418975)
30. Niu W, Qi Y, Gao P, Zhu D (2010) A meta-analysis of the bradykinin B2 receptor gene -58C/T polymorphism with hypertension. Clin Chim Acta 411(5-6):324-328
31. Lacchini R, Silva PS, Tanus-Santos JE (2010) A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol 106(5):357-361
32. Muniz JJ, Lacchini R, Rinaldi TO, Nobre YT, Cologna AJ, Martins AC, Tanus-Santos JE (2011) Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. Pharmacogenomics J
33. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE (2006) eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 41(7):1044-1049 (Pubitemid 44331568)
34. Peskircioglu L, Atac FB, Erdem SR, Deveci S, Verdi H, Ozkardes H (2007) The association between intron 4 VNTR, E298A and IVF 23 + 10G/T polymorphisms of ecNOS gene and sildenafil responsiveness in patients with erectile dysfunction. Int J Impot Res 19(2):149-153 (Pubitemid 46340833)
35. Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV, Brown NJ (2008) Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 51(2):454-459 (Pubitemid 351156432)
36. Tanus-Santos JE, Desai M, Flockhart DA (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11(8):719-725 (Pubitemid 33078242)
37. Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ (2008) The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther 83(1):122-129
38. Menashe I, Rosenberg PS, Chen BE (2008) PGA: power calculator for case-control genetic association analyses. BMC Genet 9:36 (Pubitemid 351715983)
39. Pander J, Wessels JA, Mathijssen RH, Gelderblom H, Guchelaar HJ (2011) Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. Pharmacogenomics 11(7):1011-1017
40. Ritchie MD, Motsinger AA (2005) Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics 6(8):823-834 (Pubitemid 41724356)
41. Gui J, Andrew AS, Andrews P, Nelson HM, Kelsey KT, Karagas MR, Moore JH (2011) A robust multifactor dimensionality reduction method for detecting gene-gene interactions with application to the genetic analysis of bladder cancer susceptibility. Ann Hum Genet 75(1):20-28
42. Abe K, Nakayama M, Yoshimura M, Nakamura S, Ito T, Yamamuro M, Sakamoto T, Miyamoto Y, Yoshimasa Y, Saito Y, Nakao K, Yasue H, Ogawa H (2005) Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T > C polymorphism. Pharmacogenet Genomics 15(5):329-336 (Pubitemid 40676554)
43. Mason RP, Jacob RF, Kubant R, Jacoby A, Louka F, Corbalan JJ, Malinski T (2012) Effects of angiotensin receptor blockers on endothelial nitric oxide release - The role of eNOS variants. Br J Clin Pharmacol
44. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE (2007) Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193(2):438-444 (Pubitemid 47058109)
45. Nagassaki S, Herculano RD, Graeff CF, Tanus-Santos JE (2009) eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur J Clin Pharmacol 65(4):385-392
46. Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE (2002) Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 12(5):407-413 (Pubitemid 34816420)
47. Zago AS, Kokubun E, Fenty-Stewart N, Park JY, Attipoe S, Hagberg J, Brown M (2010) Effect of physical activity and t-786C polymorphism in blood pressure and blood flow in the elderly. Arq Bras Cardiol 95(4):510-516
48. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE (2010) eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 10(1):40-45
49. Erdos EG, Tan F, Skidgel RA (2010) Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 55(2):214-220
50. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T (2000) Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 36(1):127-131 (Pubitemid 30602164)
51. Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T (2002) Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 16(12):857-863 (Pubitemid 36118911)
52. Lee YJ, Tsai JC (2001) Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 50(11):1346-1350 (Pubitemid 34007396)
53. Woo SW, Bang S, Chung MW, Jin SK, Kim YS, Lee SH (2009) Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans. J Clin Pharm Ther 34(5):561-567
54. Grilo A, Saez-Rosas MP, Santos-Morano J, Sanchez E, Moreno-Rey C, Real LM, Ramirez-Lorca R, Saez ME (2011) Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 21(1):10-17
55. Sandrim VC, Yugar-Toledo JC, Desta Z, Flockhart DA, Moreno H Jr, Tanus-Santos JE (2006) Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 24(12):2393-2397 (Pubitemid 44684687)
56. Silva PS, Fontana V, Palei AC, Sertorio JT, Biagi C, Tanus-Santos JE (2011) Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Eur J Clin Pharmacol 67(4):365-370
57. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC, Correa RX, Rios-Santos F, Tanus-Santos JE (2005) Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 12(3):177-182 (Pubitemid 40432137)